As GCC is a highly specific colon epithelial antigen that is expressed on both primary and metastatic CRC tumors as well as gastric, esophageal, and pancreatic tumors, TAK-264 may provide a novel targeted approach for the treatment of these GCC-expressing malignancies, which are diseases of unmet medical need. The gene discussed is GUCY2C; the disease is pancreatic neoplasm.